Verosudil

Verosudil is an inhibitor of Rho-associated kinase 1 (ROCK1) and ROCK2 (Ki = 2 nM for both).1 It is selective for ROCK1 and ROCK2 over PKA, PKCθ, Cdc42-binding kinase α (MRCKα), and calcium/calmodulin-dependent protein kinase IV (CaMKIV; Kis = 69, 9,332, 28, and 5,855 nM, respectively). Verosudil (1 µM) decreases focal adhesion points on, and actin fiber length in, primary porcine trabecular meshwork (PTM) cells. It inhibits TGF-β-induced increases in α-smooth muscle actin (α-SMA) levels in primary human conjunctival fibroblasts when used at concentrations of 250 or 500 nM.2 Verosudil inhibits TGF-β-induced migration in a wound healing assay using primary human conjunctival fibroblasts. It reduces intraocular pressure (IOP) in rabbits and Formosan rock monkeys when ocularly administered at a concentration of 0.5%.1 Ocular administration of verosudil (0.5%) decreases IOP and subconjunctival collagen levels in a rabbit model of trabeculectomy.2WARNING This product is not for human or veterinary use.

A ROCK1 and ROCK2 inhibitor

327.4

≥98%

Biochemicals/Kinase Inhibitors/ROCK/Microtubule Dynamics/Small Molecule Inhibitors/Kinases

Formal_Name:N-(1,2-dihydro-1-oxo-6-isoquinolinyl)-α-(dimethylamino)-3-thiopheneacetamide;Synonyms:AR-12286

O=C1NC=CC2=C1C=CC(NC(C(C3=CSC=C3)N(C)C)=O)=C2

1414854-42-4

≥ 4 years

DMSO: Soluble: =10 mg/ml Ethanol: Slightly soluble: 0.1-1 mg/ml